$MRSH

Insider Sale: CEO Dumps More Than 16,000 Shares of Financial Stock

Marsh & McLennan CEO John Q. Doyle sold 16,656 shares at $188.51 each on Sept. 2, 2026, using a 10b5-1 plan. Post-sale, he holds ~117,000 shares. The stock has a -9% one-year return. The company has a $90.4B market cap, $27.9B TTM revenue, and $4.0B net income.

Original reporting
Published Sep 17, 2026, 3:15 PM UTC
Analysis
AlphAI AI DeskAI-generated
Added to AlphAI Sep 17, 2026, 3:25 PM UTC. Informational, not investment advice.
How this was made
AlphAI summarizes source reporting and applies a structured AI analysis for relevance, timing, sentiment and ticker impact. Always verify material claims with the original publisher.
Insider Sale: CEO Dumps More Than 16,000 Shares of Financial Stock — source image
Decision brief

The 30-second read

$MRSHNeutralLow
01

Why it matters

The disclosed sale is a standard 10b5‑1 transaction with limited market impact.

02

Market read

The filing provides a factual update on insider holdings but offers little actionable insight for traders.

03

What to watch

The CEO retains a large stake (~117,000 shares) worth ~$22 M, indicating continued confidence.

Relevance 4/10Novelty 4/10Timing: Sept. 2 2026 (post‑market filing)

Background

Marsh & McLennan Companies (MRSH) is a $90 B professional services firm. The article reports a routine insider sale via a Form 4 filing.

Company-level read

Ticker impact

$MRSHNeutralMedium confidence
Context

SEC Form 4 disclosed CEO John Q. Doyle sold 16,656 shares at $188.51 each on Sept. 2, 2026.

Expected impact

Limited short‑term effect; price may stay flat unless market interprets the sale as a negative signal.

Evidence & confidence

Sale size (~$3.1 M) is small relative to market cap ($90 B) and follows a pre‑arranged 10b5‑1 plan, reducing actionable significance.

Market effects

Minimal; insider sale does not alter risk‑management or insurance brokerage sector outlook.

None; the filing is company‑specific.

None

Counterpoint

Some traders may view any insider sell as a bearish cue, potentially shorting MRSH on sentiment.

Key entities

  • John Q. Doyle

    President and CEO of Marsh & McLennan Companies

Related articles

$BROMedAI 8/10

Winners And Losers Of Q2: Baldwin Insurance Group (NASDAQ:BWIN) Vs The Rest Of The Insurance Brokers Stocks

Ryan Specialty beat estimates but fell 11.1% to $39.20. Brown & Brown (BRO) reported $1.68B revenue, up 30.4% YoY, missing estimates by 2.5%, and dropped 3.4% to $67.32. Arthur J. Gallagher (AJG) reported $4.00B revenue, up 24.3% YoY, missing estimates by 0.5%, and fell 3.3% to $248.05. Marsh (MRSH) reported $7.40B revenue, up 6.2% YoY, beating estimates by 1.8%, and dropped 1.2% to $179.91.

MedAI 8/10

Marsh McLennan Agency to acquire century-old Iowa broker Accel Group

Marsh McLennan Agency (MMA) will acquire Accel Group, a privately held Iowa-based insurance broker founded in 1936, with seven offices and 130+ employees. Accel’s services include commercial and personal insurance, employee benefits, agribusiness coverage, and wealth and retirement advisory. MMA said the deal expands rural and agribusiness capacity, following similar regional acquisitions.

$MRSHMed

Marsh & McLennan Companies Q2 Earnings Call Highlights

Marsh & McLennan (NYSE:MRSH) reported Q2 results and discussed market conditions on its earnings call. Consulting revenue rose 10% to $2.6B, with adjusted operating income up 11% to $533M. Mercer revenue was $1.6B. Marsh Global Insurance Market Index showed primary commercial rates down 6% in Q2. The company ended with $20.6B debt and $1.7B cash, and expects $5.5B capital deployment in 2026.

$MRSHMed

Marsh (NYSE:MRSH) Exceeds Q2 CY2026 Expectations

Marsh (NYSE:MRSH) reported Q2 CY2026 results. Revenue rose 6.2% year on year to $7.40 billion, exceeding Wall Street’s estimate by 1.8%, and non-GAAP EPS was $2.96, 2.3% above consensus. Adjusted operating margin was 26.9%. Analysts expect revenue growth of 4.2% and full-year EPS to rise from $10.22 to $10.90.